LIVIVO - Search results -

Search results

Result 1 - 10 of total 204

Search options

Article ; Online: iTRAQ-Based Quantitative Proteomic Analysis of Acinetobacter baumannii under Hypoxia and Normoxia Reveals the Role of OmpW as a Virulence Factor.

Gil-Marqués, María Luisa / Pachón, Jerónimo / Smani, Younes

2022 Volume 10, Issue 2, Page(s) e0232821

Abstract: Acinetobacter baumannii needs to adapt to hypoxia during infection. Understanding its proteome regulation during infection would allow us to determine new targets to develop novel treatments. iTRAQ proteomic analysis of A549 cell infection by the ATCC ... ...

Abstract	Acinetobacter baumannii needs to adapt to hypoxia during infection. Understanding its proteome regulation during infection would allow us to determine new targets to develop novel treatments. iTRAQ proteomic analysis of A549 cell infection by the ATCC 17978 strain was performed. A total of 175 proteins were differentially expressed under hypoxia versus normoxia. We selected the hypoxia-downregulated protein OmpW to analyze its role as a virulence factor. The loss of OmpW decreased the adherence and invasion of A. baumannii in these host cells, without affecting its bacterial growth. Moreover, A549 cell viability with ΔOmpW infection was higher than that with the wild-type strain. ΔOmpW presented less biofilm formation. Finally, the minimum lethal dose required by the ΔOmpW mutant was higher than that of the wild-type strain in a murine peritoneal sepsis model, with lower bacterial loads in tissues and fluids. Therefore, OmpW seems to be a virulence factor necessary for A. baumannii pathogenesis.
MeSH term(s)	Acinetobacter baumannii/genetics ; Acinetobacter baumannii/metabolism ; Animals ; Biofilms ; Hypoxia ; Mice ; Proteome/metabolism ; Proteomics ; Virulence Factors/genetics ; Virulence Factors/metabolism
Chemical Substances	Proteome ; Virulence Factors
Language	English
Publishing date	2022-03-02
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2807133-5
ISSN	2165-0497 ; 2165-0497
ISSN (online)	2165-0497
ISSN	2165-0497
DOI	10.1128/spectrum.02328-21
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Antiviral activity of immunosuppressors alone and in combination against human adenovirus and cytomegalovirus.

Carretero-Ledesma, Marta / Aguilar-Guisado, Manuela / Berastegui-Cabrera, Judith / Balsera-Manzanero, María / Pachón, Jerónimo / Cordero, Elisa / Sánchez-Céspedes, Javier

International journal of antimicrobial agents

2024 Volume 63, Issue 5, Page(s) 107116

Abstract: Human adenovirus (HAdV) and cytomegalovirus (HCMV) cause high morbidity and mortality in patients undergoing solid organ transplantation (SOT) and haematopoietic stem cell transplantation (HSCT). Immunosuppressors are used universally to prevent graft-vs- ...

Abstract	Human adenovirus (HAdV) and cytomegalovirus (HCMV) cause high morbidity and mortality in patients undergoing solid organ transplantation (SOT) and haematopoietic stem cell transplantation (HSCT). Immunosuppressors are used universally to prevent graft-vs-host disease in HSCT and graft rejection in SOT. The long-term use of these drugs is associated with a high risk of infection, but there is also evidence of their specific interference with viral infection. This study evaluated the antiviral activity of immunosuppressors commonly used in clinical practice in SOT and HSCT recipients in vitro to determine whether their use could be associated with reduced risk of HAdV and HCMV infection. Cyclophosphamide, tacrolimus, cyclosporine, mycophenolic acid, methotrexate, everolimus and sirolimus presented antiviral activity, with 50% inhibitory concentration (IC
MeSH term(s)	Humans ; Immunosuppressive Agents/pharmacology ; Antiviral Agents/pharmacology ; Adenoviruses, Human/drug effects ; Cytomegalovirus/drug effects ; Drug Synergism ; Inhibitory Concentration 50 ; Mycophenolic Acid/pharmacology ; Tacrolimus/pharmacology ; Cyclosporine/pharmacology ; Cytomegalovirus Infections/drug therapy ; Cytomegalovirus Infections/virology ; Cytomegalovirus Infections/prevention & control
Chemical Substances	Immunosuppressive Agents ; Antiviral Agents ; Mycophenolic Acid (HU9DX48N0T) ; Tacrolimus (WM0HAQ4WNM) ; Cyclosporine (83HN0GTJ6D)
Language	English
Publishing date	2024-02-23
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	1093977-5
ISSN	1872-7913 ; 0924-8579
ISSN (online)	1872-7913
ISSN	0924-8579
DOI	10.1016/j.ijantimicag.2024.107116
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3368: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 500: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Concomitant administration of seasonal influenza and COVID-19 mRNA vaccines.

Aydillo, Teresa / Balsera-Manzanero, Maria / Rojo-Fernandez, Amaya / Escalera, Alba / Salamanca-Rivera, Celia / Pachón, Jerónimo / Del Mar Muñoz-García, María / Sánchez-Cordero, María José / Sánchez-Céspedes, Javier / García-Sastre, Adolfo / Cordero, Elisa

Emerging microbes & infections

2024 Volume 13, Issue 1, Page(s) 2292068

Abstract: Current clinical guidelines support the concomitant administration of seasonal influenza vaccines and COVID-19 mRNA boosters vaccine. Whether dual vaccination may impact vaccine immunogenicity due to an interference between influenza or SARS-CoV-2 ... ...

Abstract	Current clinical guidelines support the concomitant administration of seasonal influenza vaccines and COVID-19 mRNA boosters vaccine. Whether dual vaccination may impact vaccine immunogenicity due to an interference between influenza or SARS-CoV-2 antigens is unknown. We aimed to understand the impact of mRNA COVID-19 vaccines administered concomitantly on the immune response to influenza vaccines. For this, 128 volunteers were vaccinated during the 22-23 influenza season. Three groups of vaccination were assembled: FLU vaccine only (46, 35%)
MeSH term(s)	Humans ; Antibodies, Viral ; COVID-19/prevention & control ; COVID-19 Vaccines/administration & dosage ; Influenza A Virus, H3N2 Subtype ; Influenza Vaccines/administration & dosage ; Influenza, Human/prevention & control ; mRNA Vaccines ; Seasons ; Vaccination
Chemical Substances	Antibodies, Viral ; COVID-19 Vaccines ; Influenza Vaccines ; mRNA Vaccines
Language	English
Publishing date	2024-01-18
Publishing country	United States
Document type	Journal Article
ZDB-ID	2681359-2
ISSN	2222-1751 ; 2222-1751
ISSN (online)	2222-1751
ISSN	2222-1751
DOI	10.1080/22221751.2023.2292068
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Inhibition of adenovirus transport from the endosome to the cell nucleus by rotenone.

Balsera-Manzanero, María / Ghirga, Francesca / Ruiz-Molina, Ana / Mori, Mattia / Pachón, Jerónimo / Botta, Bruno / Cordero, Elisa / Quaglio, Deborah / Sánchez-Céspedes, Javier

Frontiers in pharmacology

2024 Volume 14, Page(s) 1293296

Abstract: Regardless of the clinical impact of human adenovirus (HAdV) infections in the healthy population and its high morbidity in immunosuppressed patients, a specific treatment is still not yet available. In this study, we screened the CM1407 COST Action's ... ...

Abstract	Regardless of the clinical impact of human adenovirus (HAdV) infections in the healthy population and its high morbidity in immunosuppressed patients, a specific treatment is still not yet available. In this study, we screened the CM1407 COST Action's chemical library, comprising 1,233 natural products to identify compounds that restrict HAdV infection. Among them, we identified rotenolone, a compound that significantly inhibited HAdV infection. Next, we selected four isoflavonoid-type compounds (e.g., rotenone, deguelin, millettone, and tephrosin), namely rotenoids, structurally related to rotenolone in order to evaluate and characterized
Language	English
Publishing date	2024-01-11
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2587355-6
ISSN	1663-9812
ISSN	1663-9812
DOI	10.3389/fphar.2023.1293296
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Heteroleptic (S^C)-cyclometallated gold(III) complexes as novel antiviral agents.

Balsera-Manzanero, María / Soengas, Raquel G / Carretero-Ledesma, Marta / Ratia, Carlos / Iglesias, M José / Pachón, Jerónimo / López-Ortiz, Fernando / Cordero, Elisa / Soto, Sara M / Sánchez-Céspedes, Javier

Heliyon

2024 Volume 10, Issue 6, Page(s) e27601

Abstract: Despite the increasingly widespread clinical impact of adenovirus (HAdV) infections in healthy individuals and the associated high morbidity in immunosuppressed patients, particularly among the paediatric population, a specific treatment for this virus ... ...

Abstract	Despite the increasingly widespread clinical impact of adenovirus (HAdV) infections in healthy individuals and the associated high morbidity in immunosuppressed patients, particularly among the paediatric population, a specific treatment for this virus has yet to be developed. In this study, we report the anti-HAdV activity of sub-micromolar concentrations of four heteroleptic (C^S)-cycloaurated complexes bearing a single thiophosphinamide [
Language	English
Publishing date	2024-03-19
Publishing country	England
Document type	Journal Article
ZDB-ID	2835763-2
ISSN	2405-8440
ISSN	2405-8440
DOI	10.1016/j.heliyon.2024.e27601
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Efficacy of Lysophosphatidylcholine as Direct Treatment in Combination with Colistin against

Miró-Canturri, Andrea / Ayerbe-Algaba, Rafael / Jiménez-Mejías, Manuel Enrique / Pachón, Jerónimo / Smani, Younes

Antibiotics (Basel, Switzerland)

2021 Volume 10, Issue 2

Abstract: The stimulation of the immune response to prevent the progression of an infection may be an adjuvant to antimicrobial treatment. Here, we aimed to evaluate the efficacy of lysophosphatidylcholine (LPC) treatment in combination with colistin in murine ... ...

Abstract	The stimulation of the immune response to prevent the progression of an infection may be an adjuvant to antimicrobial treatment. Here, we aimed to evaluate the efficacy of lysophosphatidylcholine (LPC) treatment in combination with colistin in murine experimental models of severe infections by
Language	English
Publishing date	2021-02-17
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2681345-2
ISSN	2079-6382
ISSN	2079-6382
DOI	10.3390/antibiotics10020194
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Acidic Urine pH and Clinical Outcome of Lower Urinary Tract Infection in Kidney Transplant Recipients Treated with Ciprofloxacin and Fosfomycin.

Herrera-Espejo, Soraya / Fontserè, Sara / Infante, Carmen / Suárez-Benjumea, Alejandro / Carretero-Ledesma, Marta / Suñer-Poblet, Marta / González-Corvillo, Carmen / Bernal, Gabriel / Martín-Gutiérrez, Guillermo / Pérez-Cáceres, Juan Antonio / Pachón, Jerónimo / Pachón-Ibáñez, María Eugenia / Cordero, Elisa

Antibiotics (Basel, Switzerland)

2024 Volume 13, Issue 2

Abstract: Different factors, including antimicrobial resistance, may diminish the effectiveness of antibiotic therapy, challenging the management of post-transplant urinary tract infection (UTI). The association of acidic urine pH with microbiological and clinical ...

Abstract	Different factors, including antimicrobial resistance, may diminish the effectiveness of antibiotic therapy, challenging the management of post-transplant urinary tract infection (UTI). The association of acidic urine pH with microbiological and clinical outcomes was evaluated after fosfomycin or ciprofloxacin therapy in 184 kidney transplant recipients (KTRs) with UTI episodes by
Language	English
Publishing date	2024-01-24
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2681345-2
ISSN	2079-6382
ISSN	2079-6382
DOI	10.3390/antibiotics13020116
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: A lipopolysaccharide-free outer membrane vesicle vaccine protects against Acinetobacter baumannii infection

Pulido, Marina R / García-Quintanilla, Meritxell / Pachón, Jerónimo / McConnell, Michael J

Vaccine. 2020 Jan. 22, v. 38, no. 4

2020

Abstract: Outer membrane vesicles (OMVs) were isolated from an Acinetobacter strain deficient in lipopolysaccharide (LPS) due to a mutation in lpxD (IB010). Two immunizations with 10 μg of IB010 OMVs elicited total IgG, IgM, IgG1 and IgG2c titers similar to those ... ...

Abstract	Outer membrane vesicles (OMVs) were isolated from an Acinetobacter strain deficient in lipopolysaccharide (LPS) due to a mutation in lpxD (IB010). Two immunizations with 10 μg of IB010 OMVs elicited total IgG, IgM, IgG1 and IgG2c titers similar to those observed after immunization with OMVs derived from the parental strain (ATCC 19606), and IB010 OMVs plus purified LPS. Immunization with IB010 OMVs resulted in significantly reduced post-infection spleen bacterial loads and serum IL-1β and IL-6 levels compared to control mice in a disseminated sepsis model. Mice immunized with 10 μg IB010 OMVs demonstrated significant, but partial, protection (75%) against infection, whereas mice immunized with ATCC 19606 OMVs or IB010 OMVs plus purified LPS were completely protected. Immunization of mice with 100 μg of IB010 OMVs completely protected mice from infection. This study demonstrates that LPS deficient A. baumannii produces OMVs, and that immunization with these OMVs elicits protective immunity against infection.
Keywords	Acinetobacter baumannii ; blood serum ; immunity ; immunization ; immunoglobulin G ; immunoglobulin M ; interleukin-1beta ; interleukin-6 ; lipopolysaccharides ; microbial load ; models ; mutation ; sepsis (infection) ; spleen ; vaccines
Language	English
Dates of publication	2020-0122
Size	p. 719-724.
Publishing place	Elsevier Ltd
Document type	Article
ZDB-ID	605674-x
ISSN	1873-2518 ; 0264-410X
ISSN (online)	1873-2518
ISSN	0264-410X
DOI	10.1016/j.vaccine.2019.11.043
Database	NAL-Catalogue (AGRICOLA)

In stock of ZB MED Cologne/Königswinter

Zs.A 1930: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 458: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Repositioning rafoxanide to treat Gram-negative bacilli infections.

Miró-Canturri, Andrea / Ayerbe-Algaba, Rafael / Villodres, Ángel Rodríguez / Pachón, Jerónimo / Smani, Younes

The Journal of antimicrobial chemotherapy

2020 Volume 75, Issue 7, Page(s) 1895–1905

Abstract: Objectives: Repurposing drugs provides a new approach to the fight against MDR Gram-negative bacilli (MDR-GNB). Rafoxanide, a veterinary antihelminthic drug, has shown antibacterial activity in vitro against Gram-positive bacteria. We aimed to analyse ... ...

Abstract	Objectives: Repurposing drugs provides a new approach to the fight against MDR Gram-negative bacilli (MDR-GNB). Rafoxanide, a veterinary antihelminthic drug, has shown antibacterial activity in vitro against Gram-positive bacteria. We aimed to analyse the in vitro and in vivo efficacy of rafoxanide in combination with colistin against colistin-susceptible (Col-S) and colistin-resistant (Col-R) GNB. Methods: A collection of Col-S and Col-R Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella pneumoniae were used. Chequerboard and time-kill curve analyses were performed to determine the synergy between rafoxanide and colistin. Changes in membrane structure and permeability were analysed using transmission electron microscopy and fluorescence assays. A murine peritoneal sepsis model using Col-R strains of these pathogens was performed to study the efficacy of rafoxanide (10 mg/kg/24 h, IV), colistimethate sodium (CMS) (20 mg/kg/8 h, intraperitoneally) and rafoxanide (10 mg/kg/24 h, IV) plus CMS (20 mg/kg/8 h, intraperitoneally) for 72 h. Results: Rafoxanide showed MICs ≥256 mg/L for all Col-S and Col-R strains. Chequerboard and time-kill curve analyses showed that rafoxanide (1 mg/L) is more synergistic with colistin against Col-R than Col-S strains. Col-R, but not Col-S, strains treated with rafoxanide demonstrated higher membrane permeabilization. Transmission electron microscopy visualization confirmed that Col-R strains suffer morphological changes. In the murine peritoneal sepsis model with Col-R strains, rafoxanide plus CMS, compared with CMS alone, increased mouse survival to 53.8% and 73.3%, and reduced bacterial loads in tissues and blood between 2.34 and 4.99 log10 cfu/g or mL, respectively. Conclusions: Rafoxanide repurposing, as monotherapy and in combination with CMS, may address the urgent need for new treatments for infections caused by MDR-GNB.
MeSH term(s)	Acinetobacter baumannii ; Animals ; Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; Colistin/pharmacology ; Drug Resistance, Multiple, Bacterial ; Drug Synergism ; Gram-Negative Bacteria ; Mice ; Microbial Sensitivity Tests ; Rafoxanide/pharmacology
Chemical Substances	Anti-Bacterial Agents ; Rafoxanide (22F4FLA7DH) ; Colistin (Z67X93HJG1)
Language	English
Publishing date	2020-04-02
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	191709-2
ISSN	1460-2091 ; 0305-7453
ISSN (online)	1460-2091
ISSN	0305-7453
DOI	10.1093/jac/dkaa103
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1197: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 124: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Structure-Activity Relationship Studies on Diversified Salicylamide Derivatives as Potent Inhibitors of Human Adenovirus Infection.

Xu, Jimin / Berastegui-Cabrera, Judith / Chen, Haiying / Pachón, Jerónimo / Zhou, Jia / Sánchez-Céspedes, Javier

Journal of medicinal chemistry

2020 Volume 63, Issue 6, Page(s) 3142–3160

Abstract: The effective treatment of adenovirus (HAdV) infections in immunocompromised patients still poses great challenges. Herein, we reported our continued efforts to optimize a series of salicylamide derivatives as potent inhibitors of HAdV infection. Of ... ...

Abstract	The effective treatment of adenovirus (HAdV) infections in immunocompromised patients still poses great challenges. Herein, we reported our continued efforts to optimize a series of salicylamide derivatives as potent inhibitors of HAdV infection. Of these, nine compounds (
MeSH term(s)	A549 Cells ; Adenoviruses, Human/drug effects ; Antiviral Agents/chemical synthesis ; Antiviral Agents/pharmacology ; Antiviral Agents/toxicity ; DNA/metabolism ; DNA Replication/drug effects ; Humans ; Microbial Sensitivity Tests ; Molecular Structure ; Salicylamides/chemical synthesis ; Salicylamides/pharmacology ; Salicylamides/toxicity ; Structure-Activity Relationship ; Virus Internalization/drug effects
Chemical Substances	Antiviral Agents ; Salicylamides ; DNA (9007-49-2)
Language	English
Publishing date	2020-02-28
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	218133-2
ISSN	1520-4804 ; 0022-2623
ISSN (online)	1520-4804
ISSN	0022-2623
DOI	10.1021/acs.jmedchem.9b01950
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 151: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MB 1: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito